Highest-materiality recent filing
Healthpeak raises FY 2026 guidance; Q1 FFO as adj $0.45, Janus Living IPO nets $880M
Net income $0.28, Nareit FFO $0.42, FFO as adjusted $0.45 per share for Q1 2026.
Healthpeak forms Janus Living for senior housing IPO; Q4 FFO $0.47, same-store NOI +3.9%
Planned IPO of Janus Living, a dedicated senior housing REIT, to unlock value; Healthpeak to retain ownership stake.
Healthpeak Q3 net loss $0.17/sh; AFFO $0.42; same-store NOI +0.9%
GAAP net loss of $117M ($0.17 diluted) vs income $85.7M ($0.12) in Q3 2024.
Healthpeak OP completes $500M offering of 4.750% senior notes due 2033
Aggregate principal $500M, 4.750% notes due Jan 15, 2033, semi-annual interest from Jan 15, 2026.
Healthpeak Q2 net income $0.05 EPS vs $0.21 YoY; FFO as Adj. $0.46 vs $0.45
Net income $0.05 diluted EPS vs $0.21 YoY; FFO as Adjusted $0.46 vs $0.45, AFFO $0.44 vs $0.40.
Healthpeak appoints Kelvin Moses as CFO; led $5B Physicians Realty integration
Kelvin O. Moses appointed CFO effective April 24, 2025, succeeding under succession plan.
Healthpeak Q1 net income $0.06/sh, FFO as Adjusted $0.46; same-store NOI up 7%
Net income $42.4M ($0.06 diluted EPS); Nareit FFO $0.45/sh, FFO as Adjusted $0.46/sh, AFFO $0.43/sh.
Healthpeak Q4 net income $0.01/sh; dividend raised 1.7% to $0.305; leadership shifts
Q4 net income $0.01/sh; Nareit FFO $0.44; FFO as Adj $0.46; AFFO $0.40.
Healthpeak Q3 FFO as Adjusted $0.45; raises FY guidance; lab leasing 733K sq ft
Net income $0.12/share; FFO as Adjusted $0.45; AFFO $0.41; same-store cash NOI growth 4.1%.
Healthpeak reports Q2 EPS $0.21, raises FY guidance, $1.2B YTD dispositions
Net income diluted $0.21/share in Q2 2024 vs $0.09 in Q2 2023; Nareit FFO $0.44, FFO as Adjusted $0.45, AFFO $0.39.
Healthpeak merger pro forma shows 2023 diluted EPS $0.22, Q1 2024 loss $0.03
Pro forma 2023 revenue $2.77B, net income $152.7M; diluted EPS $0.22.
Healthpeak Q1 FFO as Adjusted $0.45 beats; raises full-year guidance midpoint by $0.02
Q1 net income $0.01/sh; FFO as Adj $0.45 (vs $0.42 YoY); AFFO $0.41 (vs $0.38).
Healthpeak establishes $1.5B at-the-market equity offering program
Amendment to ATM equity sales agreement executed March 11, 2024, adding up to $1.5B in common stock issuance capacity.
Healthpeak closes Physicians Realty Trust acquisition; ticker to change to DOC
Each Physicians Realty Trust common share converted into 0.674 Healthpeak shares.
Physicians Realty Trust FY2023 audited financials filed; net income $43.8M, diluted EPS $0.17
Total revenues $543.5M in 2023, up from $526.6M in 2022; net income fell to $43.8M from $110.0M.
Healthpeak stockholders and Physicians Realty shareholders approve merger; close expected March 1
Healthpeak stockholders approved stock issuance with 456.7M for, 11.9M against.
Healthpeak Q4 FFO as Adj $0.46/share; Same-store NOI +3.6%; new $236M lab JV
Q4 net income $0.13/share, Nareit FFO $0.48, FFO as Adj $0.46, AFFO $0.36; FY23 net income $0.56, Nareit FFO $1.79, FFO as Adj $1.78, AFFO $1.53.
Physicians Realty Trust provides preliminary Q4 & FY 2023 estimates ahead of Healthpeak merger
Preliminary Q4 net income $4M-$11M ($0.02-$0.04 EPS); FFO per share $0.22-$0.24.
On April 24, 2025, the Board of Directors of Healthpeak Properties, Inc. (the “Company”) appointed Kelvin O. Moses as the Company’s Chief Financial Officer and principal financial officer, effective immediately, pursuant to the Company’s succession plan.
On April 2, 2025, Peter A. Scott informed Healthpeak Properties, Inc. (the “Company”) of his resignation from his position as Chief Financial Officer of the Company.
Thomas Klaritch, currently the Company’s Chief Operating Officer, will retire from the Company.
Christine N. Garvey and David B. Henry retired from the Board of Directors (the “Board”) of Healthpeak Properties, Inc. (the “Company”) effective immediately prior to the 2024 annual meeting of stockholders held on April 25, 2024 (the “Annual Meeting”).
Christine N. Garvey and David B. Henry retired from the Board of Directors (the “Board”) of Healthpeak Properties, Inc. (the “Company”) effective immediately prior to the 2024 annual meeting of stockholders held on April 25, 2024 (the “Annual Meeting”).
appointed John T. Thomas, Tommy G. Thompson, Pamela J. Kessler, Ava E. Lias-Booker and Richard A. Weiss to the Board, with Mr. Thomas being appointed as Vice Chair of the Board
appointed John T. Thomas, Tommy G. Thompson, Pamela J. Kessler, Ava E. Lias-Booker and Richard A. Weiss to the Board, with Mr. Thomas being appointed as Vice Chair of the Board
appointed John T. Thomas, Tommy G. Thompson, Pamela J. Kessler, Ava E. Lias-Booker and Richard A. Weiss to the Board, with Mr. Thomas being appointed as Vice Chair of the Board
appointed John T. Thomas, Tommy G. Thompson, Pamela J. Kessler, Ava E. Lias-Booker and Richard A. Weiss to the Board, with Mr. Thomas being appointed as Vice Chair of the Board
appointed John T. Thomas, Tommy G. Thompson, Pamela J. Kessler, Ava E. Lias-Booker and Richard A. Weiss to the Board, with Mr. Thomas being appointed as Vice Chair of the Board
Max materiality 0.95 · Median 0.55 · Most common event other_material